secwatch / observer
8-K filed June 23, 2025, 7:59 PM ET ticker BGLC CIK 0001737523
leadership confidence high sentiment neutral materiality 0.50

BioNexus Gene Lab appoints Chong Set Fui as CFO effective immediately

BioNexus Gene Lab Corp

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Su-Leng Tan Lee

acting Chief Financial Officer and Principal Financial Officer
BGLC · BioNexus Gene Lab Corp
Effective
2025-06-17
Successor
Chong Set Fui (Angeline)
Filed
June 23, 2025, 7:59 PM ET
Concurrent with the new appointment, Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.
Appointed

Chong Set Fui (Angeline)

Chief Financial Officer and Principal Financial Officer
BGLC · BioNexus Gene Lab Corp
Effective
2025-06-17
Filed
June 23, 2025, 7:59 PM ET
On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Su-Leng Tan Lee departed as acting Chief Financial Officer and Principal Financial Officer at BioNexus Gene Lab Corp.

Action
ceased
Role
acting Chief Financial Officer and Principal Financial Officer
Exact text from the filing
Concurrent with the new appointment, Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Chong Set Fui (Angeline) was appointed as Chief Financial Officer and Principal Financial Officer at BioNexus Gene Lab Corp.

Action
appointed
Role
Chief Financial Officer and Principal Financial Officer
Exact text from the filing
On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately.
View on SEC.gov

BioNexus Gene Lab Corp filing history →

Source: SEC EDGAR
accession 0001477932-25-004754
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.